Drug Search Results
More Filters [+]

Usistapide

Alternative Names: usistapide, jnj-16269110, jnj16269110, jnj 16269110, R256918
Latest Update: 2014-07-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MTTP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Usistapide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes|Obesity|Overweight

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

R256918OBE1008

P2

Completed

Obesity

2008-10-08

CR013735

P2

Completed

Overweight|Obesity

2008-10-01

2007-000031-26

P2

Completed

Type 2 Diabetes

2008-09-12

R256918

P2

Completed

Type 2 Diabetes

2008-09-01

Recent News Events

Date

Type

Title